ELIQUIS has been compared with warfarin in a phase III trial for the prevention of stroke and systemic embolism in patients with NVAF.2
Learn more about the ARISTOTLE trial.
ELIQUIS is the only NOAC to be compared with a pre-specified aspirin treatment arm in a phase III trial in patients with NVAF considered unsuitable for warfarin.3
Learn more about the AVERROES trial.
ARISTOTLE = Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation
AVERROES = ApixabanVersus Acetylsalicylic Acid [ASA] to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment